Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.30 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14804605 | 1.00 | NPSR1 (0.35) | NPSR1KMT2AKDM4EOPRM1LMNA | |
| Hydrochloric Acid SCHEMBL3002144 | 0.98 | NPSR1 (0.34) | NPSR1KMT2AKDM4EOPRM1LMNA | |
| Hydrochloric Acid SCHEMBL30282462 | 0.98 | NPSR1 (0.34) | NPSR1KMT2AKDM4EOPRM1LMNA | |
| SCHEMBL17892425 | 0.88 | NPSR1 (0.37) | NPSR1KMT2AOPRM1LMNAMEN1 | |
| SCHEMBL4104019 | 0.87 | KMT2A (0.41) | NPSR1KMT2AKDM4EOPRM1LMNA | |
| Hydrochloric Acid SCHEMBL23363609 | 0.86 | NPSR1 (0.36) | NPSR1KMT2AMEN1CYP3A4CYP4F2 | |
| Hydrochloric Acid SCHEMBL3543814 | 0.85 | KMT2A (0.39) | NPSR1KMT2AKDM4EOPRM1LMNA | |
| SCHEMBL2237024 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL2237016 | 0.80 | NPSR1 (0.34) | NPSR1KMT2ALMNAMEN1 | |
| Formic Acid SCHEMBL29488748 | 0.80 | KDM4E (0.36) | NPSR1KMT2AKDM4EOPRM1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4712961-A2 | KRAS G12S AND G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20240417405-A1 | Substituted Spiro Derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2024-12-19 | — | — | US | disclosed |
| WO-2024238633-A2 | KRAS G12S AND G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2024-11-21 | — | — | WO | disclosed |
| CN-117730081-A | Substituted spirocyclic derivatives | 詹森药业有限公司 | 2024-03-19 | — | — | CN | disclosed |
| EP-4334320-A1 | SUBSTITUTED SPIRO DERIVATIVES | JANSSEN Pharmaceutica NV (BE) | 2024-03-13 | — | — | EP | disclosed |
| CN-111417635-B | Pyrazolopyrimidines with anti-Respiratory Syncytial Virus (RSV) activity | 爱尔兰詹森科学公司 | 2024-01-02 | — | — | CN | disclosed |
| EP-3240572-B1 | BENZAMIDE IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-11-01 | — | — | EP | disclosed |
| CN-115551841-A | Azetidin-3-ylcarbinol derivatives as modulators of the CCR6 receptor | 爱杜西亚药品有限公司 | 2022-12-30 | — | — | CN | disclosed |
| WO-2022237627-A1 | SUBSTITUTED SPIRO DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2022-11-17 | — | — | WO | disclosed |
| WO-2022166991-A1 | INDOLINE COMPOUND | 南京明德新药研发有限公司 | 2022-08-11 | — | — | WO | disclosed |
| WO-2011033053-A1 | MACROCYCLIC INHIBITORS OF JAK | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-24 | — | — | WO | disclosed |
| US-20110071179-A1 | MACROCYCLIC INHIBITORS OF JAK | JAHANGIR ALAM | 2011-03-24 | — | — | US | disclosed |
| EP-2245033-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2010-11-03 | — | — | EP | disclosed |
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2010-10-21 | — | — | US | disclosed |
| US-20100190764-A1 | Novel compounds | GLAXO GROUP LIMITED | 2010-07-29 | — | — | US | disclosed |
| US-20100190764-A1 | Novel compounds | GLAXO GROUP LIMITED | 2010-07-29 | — | — | US | disclosed |
| EP-2178823-A1 | SPIRO CYCLOPENTANE COMPOUNDS USEFUL AS ANTAGONISTS OF THE H1-RECEPTOR | Glaxo Group Limited (GB) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009106441-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009016084-A1 | SPIRO CYCLOPENTANE COMPOUNDS USEFUL AS ANTAGONISTS OF THE H1-RECEPTOR | GLAXO GROUP LIMITED (GB) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009016084-A1 | SPIRO CYCLOPENTANE COMPOUNDS USEFUL AS ANTAGONISTS OF THE H1-RECEPTOR | GLAXO GROUP LIMITED (GB) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190764-A1 | Novel compounds | HCRTR1, HCRTR2, CNR1 | NPSR1 13/4885KMT2A 1721/4885KDM4E 2231/4885 |
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | SYK, ZAP70, TYK2 | NPSR1 1068/4885KMT2A 1366/4885KDM4E 581/4885 |
| US-20240417405-A1 | Substituted Spiro Derivatives | BMI1, MLLT1, MLLT3 | NPSR1 4230/4885KMT2A 154/4885KDM4E 671/4885 |
| US-20110071179-A1 | MACROCYCLIC INHIBITORS OF JAK | JAK2, JAK1, JAK3 | NPSR1 4005/4885KMT2A 895/4885KDM4E 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.